Skip to main content

Table 2 A summary of the scores obtained by VAS questionnaire

From: Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

 

Univariable

Multivariable

Mean ± SD

Median (IQR)

P-value

Coefficient (95% CI)

P-value

Group

 Active

3.27 ± 0.88

3 (1)

0.0001

Reference

0.0001

 Placebo

5.87 ± 1.02

6 (2)

2.58 (2.11, 3.06)

Sex

 Female

4.56 ± 1.52

5 (3)

0.771

0.09 (−0.48, 0.65)

0.761

 Male

4.48 ± 1.83

4 (3)

Reference

Marital Status

 Single

4.67 ± 1.58

4 (3)

0.582

0.25 (−0.41, 0.92)

0.452

 Married

4.45 ± 1.65

4.5 (3)

Reference

Duration of Migraine

 ≤2 years

4.58 ± 1.63

4.50 (3)

0.710

0.30 (−0.23, 0.84)

0.262

 > 2 years

4.46 ± 1.62

4 (3)

Reference

Age (rho)

- 0.05

0.711

0.02 (−0.02, 0.06)

0.277

BMI (rho)

- 0.06

0.648

- 0.03 (−0.14, 0.08)

0.567

Number of attack pre-treatment (rho)

0.15

0.232

0.27 (0.01, 0.54)

0.007

  1. BMI Body–mass index, SD Standard deviation, IQR Interquartile range, rho Spearman correlation coefficient